1
|
Sui HT, Gao HD, Zhao RY, Guo Y, Su JF, Shu X. [Analysis of influenza vaccination status and immunization strategy in high-risk population]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45:615-620. [PMID: 38678362 DOI: 10.3760/cma.j.cn112338-20230718-00016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2024]
Abstract
Influenza is a contagious respiratory disease caused by influenza viruses, and the burden of severe disease is commonly seen in high risk populations. Influenza vaccination is an effective way to prevent influenza and its complications, especially for high risk populations. Although some countries have included influenza vaccine in their national immunization programs, influenza vaccination rates remain low globally in high risk populations. The influenza vaccine in China is still a non-immunization program vaccine that is voluntarily vaccinated at its own expense, and the influenza vaccine immunization strategy is different across the country. There is still a gap between the vaccination rate of the influenza vaccine and that of developed countries. It is an urgent problem to further optimize the whole population immunization strategy of influenza vaccine in China, strengthen the publicity of the whole population immunization strategy of influenza vaccine, and reduce the disease burden of influenza in China.
Collapse
Affiliation(s)
- H T Sui
- China National Biotec Group, Beijing 100024, China
| | - H D Gao
- China National Biotec Group, Beijing 100024, China
| | - R Y Zhao
- China National Biotec Group, Beijing 100024, China
| | - Y Guo
- China National Biotec Group, Beijing 100024, China
| | - J F Su
- China National Biotec Group, Beijing 100024, China
| | - X Shu
- China National Biotec Group, Beijing 100024, China
| |
Collapse
|
2
|
Sui HT, Guo Y, Zhao RY, Su JF, Shu X. [Adult vaccination immunization strategies and research progress worldwide]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:1327-1333. [PMID: 37661629 DOI: 10.3760/cma.j.cn112338-20230505-00277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
Vaccination is the most cost-effective measure to prevent infectious diseases in both children and adults. At present, the global burden of infectious diseases in adults is still heavy. With the continuous development and improvement of vaccines, vaccination has shown great potential to prevent infectious diseases, further reduce the morbidity and mortality of infectious diseases in adults and improve people's life quality. This article summarizes the current status of adult immunization, immunization strategies of representative countries, different adult vaccination strategies, and the advantages and challenges of adult immunization to provide reference for further exploring adult immunization strategies and improving adult vaccination recommendations. More attention should be paid to the immunization strategies for different adult populations, and effective measures should be taken to improve the vaccination coverage for the better protection of people's life and health.
Collapse
Affiliation(s)
- H T Sui
- China National Biotec Group, Beijing 100024, China
| | - Y Guo
- China National Biotec Group, Beijing 100024, China
| | - R Y Zhao
- China National Biotec Group, Beijing 100024, China
| | - J F Su
- China National Biotec Group, Beijing 100024, China
| | - X Shu
- China National Biotec Group, Beijing 100024, China
| |
Collapse
|
3
|
Sui HT, Guo Y, Yang ZN, Su JF, Shu X, Zhang Y, Yang XM. [Research progress of influenza vaccination, pneumococcal vaccination and COVID-19 vaccination among cancer patients]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:100-106. [PMID: 36655265 DOI: 10.3760/cma.j.cn112150-20220413-00353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
This article reviews the relevant studies on the efficacy and safety of influenza, pneumococcal and COVID-19 vaccination among tumor patients worldwide in recent years. By combing and analyzing the retrieved literature, the results show that influenza and pneumococcal vaccination can significantly reduce the morbidity and hospitalization rate of infectious diseases in tumor patients, reduce the risk of cardiovascular events and death, and significantly improve survival prognosis. COVID-19 vaccination can also protect tumor patients, especially those who have completed full dose vaccination. Authoritative guidelines and consensuses worldwide all recommend that tumor patients receive influenza, pneumococcal and COVID-19 vaccines. We should carry out relevant researches, as well as take effective measures to strengthen patient education, so that tumor patients can fully experience the health protection brought by the vaccine to this specific group.
Collapse
Affiliation(s)
- H T Sui
- China National Biotec Group, Beijing 100029, China
| | - Y Guo
- China National Biotec Group, Beijing 100029, China
| | - Z N Yang
- China National Biotec Group, Beijing 100029, China
| | - J F Su
- China National Biotec Group, Beijing 100029, China
| | - X Shu
- China National Biotec Group, Beijing 100029, China
| | - Y Zhang
- China National Biotec Group, Beijing 100029, China
| | - X M Yang
- China National Biotec Group, Beijing 100029, China National United Vaccine Engineering Technology Research Center, Wuhan 430207, China
| |
Collapse
|
4
|
Sui HT, Guo Y, Yang ZN, Su JF, Shu X, Zhang Y, Wang HQ, Yang X. [Progress in research of influenza vaccine and 23 valent pneumococcal polysaccharide vaccine immunization in patients with chronic obstructive pulmonary disease]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:1508-1512. [PMID: 36117362 DOI: 10.3760/cma.j.cn112338-20220328-00236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
A comprehensive review of the research of the effectiveness of influenza vaccine and 23 valent pneumococcal polysaccharide vaccine (PPV23) in patients with chronic obstructive pulmonary disease (COPD) both at home and abroad in recent years showed that influenza vaccine and PPV23 immunization can significantly reduce the risk for influenza and pneumonia in COPD patients, and reduce the acute exacerbation of disease and related hospitalization. In particular, the influenza vaccination can also reduce the risk for ischemic heart disease, acute coronary syndrome, ventricular arrhythmia, lung cancer, dementia and death in the patients, and the immunization of both vaccines has a more significant protective effect. It is recommended by authoritative guidelines both at home and abroad that COPD patients can receive influenza vaccine and PPV23. At present, the coverage of domestic influenza and pneumococcal vaccines are low, and there are less studies in the applications of both vaccines in patients with COPD. Effective measures should be taken to strengthen the health education and increase the vaccination coverage. Additionally, the clinical research of influenza vaccine and PPV23 for COPD patients, especially the analysis on clinical benefit of immunization of both vaccines, should be further strengthened to effectively improve the survival and prognosis of COPD patients.
Collapse
Affiliation(s)
- H T Sui
- China National Biotec Group, Beijing 100024, China
| | - Y Guo
- China National Biotec Group, Beijing 100024, China
| | - Z N Yang
- China National Biotec Group, Beijing 100024, China
| | - J F Su
- China National Biotec Group, Beijing 100024, China
| | - X Shu
- China National Biotec Group, Beijing 100024, China
| | - Y Zhang
- China National Biotec Group, Beijing 100024, China
| | - H Q Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | | |
Collapse
|
5
|
Sui HT, Guo Y, Zhao J, Yang ZN, Su JF, Yang Y, Wang Q, Feng LZ. [Progress in research of safety, efficiency and vaccination status of influenza vaccine in populations at high risk]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:436-439. [PMID: 35345303 DOI: 10.3760/cma.j.cn112338-20210227-00153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
This paper reviews the domestic and foreign studies published in 2020 on the application of influenza vaccine in populations at high risk. The importance of influenza vaccination in population at high risk has been proved by larger sample, multicentre, high-quality evidence-based studies. Influenza vaccination is the most cost-effective measure to prevent influenza. However, the coverage rate of influenza vaccine is very low in China, it is necessary to strengthen the health education to promote influenza vaccination in different populations. It is recommended to give influenza vaccination to the population in whom influenza vaccination has been proven safe and effective before influenza season. Research of the safety, efficiency and cost-effectiveness of influenza vaccine should be accelerated for the populations in whom such data are lacking or insufficient.
Collapse
Affiliation(s)
- H T Sui
- China National Biotec Group Company Limited, Beijing 100024, China
| | - Y Guo
- China National Biotec Group Company Limited, Beijing 100024, China
| | - J Zhao
- China National Biotec Group Company Limited, Beijing 100024, China
| | - Z N Yang
- China National Biotec Group Company Limited, Beijing 100024, China
| | - J F Su
- China National Biotec Group Company Limited, Beijing 100024, China
| | - Y Yang
- Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Q Wang
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - L Z Feng
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| |
Collapse
|